Opendata, web and dolomites

MBLIs SIGNED

New Approaches to Metallo-β-Lactamase Inhibitors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MBLIs project word cloud

Explore the words cloud of the MBLIs project. It provides you a very rough idea of what is the project "MBLIs" about.

mbl    obtain    reporter    chemistry    equilibrated    organic    least    clinical    penicillin    clear    die    public    utility    antibiotic    selectivity    little    inactive    nmr    bacterial    relevance    pioneer    medicinal    panel    structural    dcc    unrelated    representative    compounds    breadth    infections    broad    inhibitors    screening    caused    acids    phosphonates    representing    blas    sbl    generation    binding    beta    resistance    clinically    metallo    modified    billion    contain    efficacy    catalyse    healthcare    esi    inhibited    60    occurrence    health    coupled    synthesis    inspire    critical    alarming    mbls    denaturing    therapies    biological    lactamases    pathogens    ring    spectrum    declining    structures    unlike    protein    threat    rendering    lactam    almost    mbli    mechanisms    inhibition    mechanistically    desired    hydrolysis    bla    25    phosphinic    biology    society    pbps    resistant    molecules    31p    human    enzymes    situation    gt    interdisciplinary    variations    spends    ms    sites    serious    combination    directed    dcls    mechanism    serine    mblis    structurally    global    patients    small    antibiotics    active   

Project "MBLIs" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD 

Organization address
address: WELLINGTON SQUARE UNIVERSITY OFFICES
city: OXFORD
postcode: OX1 2JD
website: www.ox.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://schofield.chem.ox.ac.uk/mariosmarkoulides.aspx
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) coordinator 183˙454.00

Map

 Project objective

The increasing problem of antibiotic resistance is a major global public health concern. In the EU 25,000 patients die each year due to infections caused by multi-resistant bacterial pathogens, and the EU spends at least 1.5 billion euro per year on healthcare costs. The β-lactam antibiotics are the most important antibiotics representing >60% of small molecules in clinical use. BLAs contain a β-lactam ring which is critical for penicillin-binding protein inhibition. However, BLA efficacy is declining due to resistance mechanisms including the widespread occurrence of β-lactamases, which catalyse β-lactam hydrolysis. Metallo-β-lactamases, long-considered as of little clinical relevance, now present a serious global threat to almost all BLAs, rendering the development of approaches to MBL inhibitors important. Unlike the serine β-lactamases, the MBLs are structurally and mechanistically unrelated to PBPs, and are not inhibited by current mechanism-based SBL inhibitors. Due to variations in MBL structures, a major challenge in MBL inhibition is the development of compounds with the breadth of selectivity necessary for clinical utility. Society is now in an alarming situation and there is a clear need for the development of an MBLI:β-lactam-based combination therapies. The aim of my proposed work is to pioneer, enable and inspire the generation of broad-spectrum MBLIs active against a panel of clinically representative MBLs, but inactive against human enzymes with related active sites. To obtain the desired objective, novel approaches are proposed and include the use of phosphonates and phosphinic acids for: (a) MBL-directed DCC coupled to analysis by non-denaturing ESI-MS and 31P-NMR, (b) 31P-NMR reporter screening method, (c) pre-equilibrated DCLs for MBL-directed DCC, and (d) the synthesis of modified inhibitors. The study will be interdisciplinary and encompass organic synthesis, biological MS/NMR, structural biology, and medicinal chemistry.

 Publications

year authors and title journal last update
List of publications.
2016 David Yuxin Wang, Martine I Abboud, Marios S Markoulides, Jürgen Brem, Christopher J Schofield
The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam
published pages: 1063-1084, ISSN: 1756-8919, DOI: 10.4155/fmc-2016-0078
Future Medicinal Chemistry 8/10 2019-06-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MBLIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MBLIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

LiverMacRegenCircuit (2020)

Elucidating the role of macrophages in liver regeneration and tissue unit formation

Read More  

CYBERSECURITY (2018)

Cyber Security Behaviours

Read More  

ErgThComplexSys (2020)

Ergodic theory for complex systems: a rigorous study of dynamics on heterogeneous networks

Read More